The Therapeutic Goods
Administration (TGA) has added
Olaparib as an orphan drug.
Olaparib is manufactured by
AstraZeneca as an oral therapy
indicated under specific conditions
for the treatment of ovarian,
fallopian tube or primary peritoneal
cancer.
Orphan drugs are those that are
intended to treat a rare disease
or are not commercially viable to
supply to treat another disease or
condition.
The designation of an orphan
drug by the TGA is a step required
before registering it on the
Australian Register of Therapeutic
Goods.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.